ERBB2 and metastatic malignant neoplasm: Since the 1980s, treatment of breast cancer has seen revolutionary improvements with the introduction of new chemotherapeutic agents, new categories of hormone agents, several agents targeting HER2, and multiple additional targeted therapies some of which have improved patient survival, including in some subtypes of metastatic cancer [22–24].